Search research articles
Contact Us
Filters
Showing results (11-20 of 18) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 18 results.
Foods (Basel, Switzerland)
|
September 13, 2025
Formation Mechanism of Characteristic Flavor Substances in 3-Year-Old Diannan Small-Ear Pig Ham: Lipidomics and Flavoromics Study
Wenli Tao, Zhenzhu Li, Guangqiang Wei, et al.
Food Research International (Ottawa, Ont.)
|
November 21, 2025
GC-O-MS volatilomics combined lipidomics revealed the key volatile flavor compounds and their precursor in fermented cream driven by Lactiplantibacillus plantarum B22
Yunmei Chai, Zhenzhu Li, Guangqiang Wei, et al.
Journal of Agricultural and Food Chemistry
|
September 17, 2025
Identification and Taste Presentation Characteristics of Umami Peptides from Hybrid Pork Duroc × (Gaoligongshan × Saba) Based on Peptidomics, Machine Learning, Molecular Docking, and Molecular Dynamics Simulation
Yuzhu Wang, Wentao Zheng, Daodian Wang, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
May 3, 2015
Pharmacokinetics and Pharmacodynamics of the SGLT2 Inhibitor Remogliflozin Etabonate in Subjects with Mild and Moderate Renal Impairment
Robin O'Connor-Semmes, Susan Walker, Anita Kapur, et al.
Molecules (Basel, Switzerland)
|
February 10, 2024
The Graphene Quantum Dots Gated Nanoplatform for Photothermal-Enhanced Synergetic Tumor Therapy
Lipin Wang, Wenbao Wang, Yufang Wang, et al.
Journal of Clinical Laboratory Analysis
|
April 15, 2025
A Large-Scale Retrospective Study of Serum Des-Gamma-Carboxy Prothrombin as a Diagnostic Marker of HCC: Effect of Liver Function on Specificity
Hongying Bu, Weijia Luo, Wenli Tao, et al.
BMC Pharmacology & Toxicology
|
May 15, 2013
First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus
Anita Kapur, Robin O'Connor-Semmes, Elizabeth K Hussey, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
August 2, 2012
Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies
James F Sigafoos, Gary D Bowers, Stephen Castellino, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 18) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 18 results.
Foods (Basel, Switzerland)
|
September 13, 2025
Formation Mechanism of Characteristic Flavor Substances in 3-Year-Old Diannan Small-Ear Pig Ham: Lipidomics and Flavoromics Study
Wenli Tao, Zhenzhu Li, Guangqiang Wei, et al.
Food Research International (Ottawa, Ont.)
|
November 21, 2025
GC-O-MS volatilomics combined lipidomics revealed the key volatile flavor compounds and their precursor in fermented cream driven by Lactiplantibacillus plantarum B22
Yunmei Chai, Zhenzhu Li, Guangqiang Wei, et al.
Journal of Agricultural and Food Chemistry
|
September 17, 2025
Identification and Taste Presentation Characteristics of Umami Peptides from Hybrid Pork Duroc × (Gaoligongshan × Saba) Based on Peptidomics, Machine Learning, Molecular Docking, and Molecular Dynamics Simulation
Yuzhu Wang, Wentao Zheng, Daodian Wang, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
May 3, 2015
Pharmacokinetics and Pharmacodynamics of the SGLT2 Inhibitor Remogliflozin Etabonate in Subjects with Mild and Moderate Renal Impairment
Robin O'Connor-Semmes, Susan Walker, Anita Kapur, et al.
Molecules (Basel, Switzerland)
|
February 10, 2024
The Graphene Quantum Dots Gated Nanoplatform for Photothermal-Enhanced Synergetic Tumor Therapy
Lipin Wang, Wenbao Wang, Yufang Wang, et al.
Journal of Clinical Laboratory Analysis
|
April 15, 2025
A Large-Scale Retrospective Study of Serum Des-Gamma-Carboxy Prothrombin as a Diagnostic Marker of HCC: Effect of Liver Function on Specificity
Hongying Bu, Weijia Luo, Wenli Tao, et al.
BMC Pharmacology & Toxicology
|
May 15, 2013
First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus
Anita Kapur, Robin O'Connor-Semmes, Elizabeth K Hussey, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
August 2, 2012
Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies
James F Sigafoos, Gary D Bowers, Stephen Castellino, et al.
Page
of 2